MedTrace Logo

Phase 1 Pharmacokinetics of Intravenous Nexium in Children

NCT00474019 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of this research study is to evaluate how much of repeated once daily intravenous (IV, meaning through a vein) doses of esomeprazole gets into the bloodstream of hospitalized children aged 0-17 years old that require acid suppression therapy.

Conditions

  • Pharmacokinetics

Interventions

DRUG

esomeprazole

IV qd for 4 days

Sponsors & Collaborators

Principal Investigators

  • Kurt Brown, MD · AstraZeneca

  • Per Lundborg, MD · AstraZeneca

  • Jill McGuinn · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Completion
2009-10-31

Countries

  • United States
  • Australia
  • Belgium
  • Hungary
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00474019 on ClinicalTrials.gov